5I2I
Structure of cetuximab Fab with cyclic F3Q variant of the meditope
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | ROTATING ANODE |
Source details | RIGAKU MICROMAX-007 HF |
Temperature [K] | 100 |
Detector technology | IMAGE PLATE |
Collection date | 2011-07-11 |
Detector | RIGAKU RAXIS IV++ |
Wavelength(s) | 1.5418 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 63.970, 82.500, 211.880 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 32.948 - 2.551 |
R-factor | 0.1618 |
Rwork | 0.160 |
R-free | 0.20480 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 4gw1 |
RMSD bond length | 0.007 |
RMSD bond angle | 0.875 |
Data reduction software | XDS |
Data scaling software | XSCALE |
Phasing software | MOLREP |
Refinement software | PHENIX ((1.10_2155)) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 35.000 | 2.620 |
High resolution limit [Å] | 2.550 | 2.550 |
Number of reflections | 37040 | |
<I/σ(I)> | 17.8 | 3.68 |
Completeness [%] | 99.0 | 90.1 |
Redundancy | 4 | 3.3 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, HANGING DROP | 293 | 0.1 M citric acid, 0.1 M sodium phosphate dibasic, 0.5 M potassium phosphate dibasic, 1.6 M sodium phosphate monobasic |